SCHEDULE: Vanguard Group Disaggregates Boston Scientific Stake

The Vanguard Group reports 0% beneficial ownership in Boston Scientific Corp following an internal realignment, shifting reporting to subsidiaries.

Summary

• The Vanguard Group filed an Amendment No. 11 to Schedule 13G for Boston Scientific Corp.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares of Boston Scientific Corp common stock, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions will report their beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update regarding The Vanguard Group's internal reporting structure, with no direct positive or negative implications for Boston Scientific Corp's operational or financial performance.

Future Outlook

NA

Management Comments

• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, leading to certain subsidiaries and business divisions reporting beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large institutional investors to adjust their reporting structures, often due to internal reorganizations or regulatory interpretations. It does not indicate a change in investment strategy towards Boston Scientific Corp by Vanguard's underlying funds, but rather a change in how that ownership is aggregated and reported at the parent level.

Stakeholder Impact

• Shareholders of Boston Scientific Corp: No direct impact on their holdings or the company's operations. The change is in how a large institutional investor's ownership is reported.
• The Vanguard Group's clients: May see beneficial ownership reported under different Vanguard entities, but the underlying investment strategy remains the same.

Key Dates

Keywords

Vanguard Group, Boston Scientific Corp, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Investment Management, Disaggregation